CASC3 and neoplasm: And late treatment with BP-Combo, beginning when tumor volumes reached appropriately 50 mm3, also exerted a more prominent inhibitory role on xenograft growth of both HeLa (Fig. 6d, e; Supplementary Fig. 9d) and Hepa1-6 (Fig. 6f, g; Supplementary Fig. 9e) cancer cells, compared with BTZ or PD0166285 monotreatment.